Kornimate/medical-research-clean huggingface dataset:
exercise and flax-based nutritional supplementation for lowering cholesterol

Conditions: Metabolic Syndrome; Osteoporosis

Summary: the purpose of our study is to use a flaxseed-based nutritional supplement in combination with exercise training (walking) for improving cholesterol levels. we hypothesize that exercise training will improve cholesterol profile and that adding supplementation with a flaxseed nutritional supplement will further improve cholesterol profile.

flax supplementation and exercise training each have small beneficial effects for improving blood lipid profile and reducing cardiovascular disease risk. flax lignan, a phytoestrogen found in flaxseed is thought to be the active compound responsible for the cholesterol-lowering effect of flaxseed. our purpose is to combine an exercise training program (walking) with flax lignan supplementation for improving blood lipid profile. comparisons: walking (6 days per week) plus flax lignan (500 mg per day) compared to walking plus placebo.

Eligibility criteria:
inclusion criteria: * 50 years or older exclusion criteria: * currently taking medication for cholesterol * smoker * diabetic * gastrointestinal disease * females on hormone replacement therapy * currently taking a flaxseed supplement * currently engaged in vigorous exercise training

Keywords: cholesterol high density lipoprotein low density lipoprotein triglyceride glucose exercise fitness flax lignan phytoestrogen bone
study of robatumumab (sch 717454, mk-7454) in combination with different treatment regimens in participants with advanced solid tumors (p04722, mk-7454-004)

Conditions: Neoplasms

Summary: this is a phase 1b/2, non-randomized, dose-escalation, multicenter, open-label study designed to evaluate the safety and tolerability of robatumumab (sch 717454, mk-7454) in combination with standard treatment in participants with advanced solid tumors to be conducted in conformance with good clinical practices. six different treatment regimens will be investigated in combination with robatumumab. the study will be divided into two parts. part 1 will consist of initial safety evaluation and dose-finding of robatumumab in combination with each treatment regimen. part 2 will consist of an expansion of each robatumumab regimen at a newly established dose level, to better define safety, tolerability, and initial efficacy in specific target populations.


Eligibility criteria:
inclusion criteria: * be willing and able to provide written informed consent for the study. * be ±18 years of age of either sex and of any race/ethnicity; * part 1: have a histologically or cytologically confirmed advanced malignant solid tumor; * part 2: have a histologically or cytologically confirmed, with measurable disease (as defined by response evaluation criteria in solid tumors \[recist\]), advanced, malignant solid tumor. * have an eastern cooperative oncology group (ecog) performance status of \<=2. * have adequate organ function within 3 weeks prior to first study drug administration. exclusion criteria: * not have known treated or untreated leptomeningeal metastasis or a metastatic central nervous system lesion. * not have a history of another malignancy * not have received prior therapy with any anti-insulin-like growth factor receptor 1 (anti-igf-1r) monoclonal antibody. * not have received radiation therapy within 2 weeks prior to first study drug administration. * not have received radiation therapy to \>25% of his/her total bone marrow during his/her lifetime. * not have undergone major surgery within 3 weeks prior to first study drug administration. * not have known human immunodeficiency virus (hiv) infection or a known hiv-related malignancy. * not have known active hepatitis b or c. * not have any serious or uncontrolled infection. * not have uncontrolled diabetes mellitus. * not have had any of the following within 6 months prior to first study drug administration: myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, clinically significant cardiac dysrhythmia or clinically significant electrocardiogram (ecg) abnormality, cerebrovascular accident or transient ischemic attack, or seizure disorder.

Keywords: antibodies, neoplasm
paclitaxel plus carboplatin with or without endostar in patients with advanced non-small cell lung cancer

Conditions: Advanced Non-small Cell Lung Cancer

Summary: in this randomized, double-blind, placebo-controlled, multicentre trial, 126 patients between july 5, 2007 and july 30, 2008 were enrolled from 10 centers. the leader units are shanghai chest hospital affiliated to shanghai jiao-tong university and shanghai changzheng hospital. all eligible patients received 1 cycle (21 days) of tc chemotherapy. after chemotherapy, patients evaluated as sd (stable disease) or above were randomized to receive endostar plus tc or tc alone for 3 cycles, 21 days as one cycle.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed, previously untreated stage iiib or iv nsclc * age of 18-75 years * at least one measurable lesion (recist) * patients evaluated as sd or above after 1 cycle (21 days) of tc chemotherapy . * adequate hematologic, cardiac, renal, and hepatic function * ecog ps 0-2 exclusion criteria: * symptomatic brain metastases * bone metastases with complications * major organ dysfunction * bleeding diathesis or coagulopathy * pregnant or lactating woman

Keywords: non-small cell lung cancer endostar paclitaxel carboplatin
efficacy of camouflaged syringe vs conventional syringe

Conditions: Dental Anxiety; Behavior

Summary: this study evaluates the efficacy of camouflage syringe vs conventional syringe in reducing dental anxiety and increasing behaviour rating.half of the participants received local anesthesia using camouflaged syringe, while others received using conventional syringe.

dental anxiety and phobia result in avoidance of dental care. since the injection itself can be painful, pain reduction procedures warrant continued investigation. camouflage design deals with the visual impact of the needle and syringe though the tactile sensation remains unaltered. in our study, post treatment anxiety levels in camouflaged syringe was reduced as compared to conventional syringe group and this might be because, patients with low anxiety tend to have high pain thresholds.

Eligibility criteria:
inclusion criteria: * retained teeth, * badly carious teeth, * mobile teeth * requiring a dental procedure under local anesthesia were selected. exclusion criteria: * mentally challenged children * those with medical conditions contraindicating the use of local anesthesia and / or surgical procedures

Keywords: anxiety camouflaged syringe conventional syringe
a prospective, randomized trial of histoacryl injection versus thrombin in the control of acute gastric variceal bleeding

Conditions: Ulcer, on Gastric Varices; Rebleeding From Gastric Varices

Summary: though histoacryl injection is now regarded as treatment of choice in the control of gastric variceal hemorrhage, it may be associated with a lot of complications such as ulcers, ulcer bleeding, bacterial infections, distant site thrombosis and cerebral vascular accident. on the other hand, thrombin has been shown to be effective in acute hemostasis of bleeding gastric varices, ranging from 70% to 100% has been recorded. the rebleeding rates were between 7% and 50%. moreover, the benefits of thrombin injection include safety, without inducing ulcers or ulcer bleeding. no incidence of distant thrombosis has ever been reported.

previous studies have proven that the use of cyanoacrylate glue injection was superior to eis or evl in arresting acute gastric variceal bleeding. endoscopic obturation with glue injection has gained worldwide popularity except the united states. the hemostatic rates of glue injection ranged from 87% to 100%, with rebleeding rates about 7% to 71%. though histoacryl injection is now regarded as treatment of choice in the control of gastric variceal hemorrhage, it may be associated with a lot of complications such as ulcers, ulcer bleeding, bacterial infections, distant site thrombosis and cerebral vascular accident. on the other hand, thrombin has been shown to be effective in acute hemostasis of bleeding gastric varices, ranging from 70% to 100% has been recorded. the rebleeding rates were between 7% and 50%. moreover, the benefits of thrombin injection include safety, without inducing ulcers or ulcer bleeding. no incidence of distant thrombosis has ever been reported. the mechanism of hemostasis induced by thrombin is through the conversion of fibrinogen to fibrin and enhancement of platelets aggregation. this trial aimed to compare the relative efficacy and safety between histoacryl injection and thrombin injection in the prevention of gastric variceal rebleeding.

Eligibility criteria:
inclusion criteria: * 1.the etiology of portal hypertension is cirrhosis. 2.age ranges between 20-80 y/o. 3.patients presenting with history of gastric variceal bleeding or acute gastric variceal bleeding proven by emergency endoscopy exclusion criteria: * 1) association with severe systemic illness, such as sepsis, cva, copd, advanced carcinoma, hepatocellular carcinoma (barcelona club liver cancer class c or d) 2) presence of massive ascites 3), serum creatinine \>3mg/dl, hepatic encephalopathy \> stage ii, 4) serum bilirubin \> 10mg/dl 5) life expectancy less than 24 hours 6) child-pugh's scores \> 13 7) pregnancy 8) has ulcers on gastric varices 9) uncooperative

Keywords: gastric varices, thrombin, histoacryl
is ultrasound-guided steroid injection less effective in carpal tunnel syndrome patients with bifid median nerve?

Conditions: Carpal Tunnel Syndrome

Summary: the aim of this study is to evaluate the short-term efficacy of ultrasound-guided corticosteroid injection in patients with and without bifid median nerve.

twenty-five patients with bifid median nerve and twenty-five patients without bifid median nerve, aged 18-65, who applied to the physical therapy and rehabilitation outpatient clinic at beylikdüzü state hospital, diagnosed with mild to moderate carpal tunnel syndrome based on electrophysiological studies, and who received ultrasound-guided corticosteroid injection, will be included in our study. patients identified as having a bifid median nerve during the injection will be noted and invited for a follow-up at the 1st month to assess their pain and functional status. the same follow-up visit will be conducted for an equal number of age- and gender-matched patients without bifid median nerve who received the injection. at the end of the study, the 1-month efficacy of the injection in both groups will be evaluated. patients who agree to participate in the study will be asked to complete the visual analog scale (vas), the boston carpal tunnel syndrome questionnaire (bctq), and the quick disabilities of the arm, shoulder, and hand questionnaire (quick-dash) before the injection. they will then be invited for a follow-up visit at the 1st month, where the vas, bctq, and quick-dash will be administered again.

Eligibility criteria:
inclusion criteria: * patients aged 18-65. * diagnosed with mild to moderate carpal tunnel syndrome based on electrophysiological studies conducted within the last 6 months. * scheduled for ultrasound-guided corticosteroid injection. * patients who have agreed to participate in the study. exclusion criteria: * diagnosis of any other condition that could cause neuropathic symptoms, such as polyneuropathy, brachial plexopathy, or thoracic outlet syndrome. * previous history of injection or surgery for carpal tunnel syndrome * patients who refuse to participate in the study.
optimalization of nephroprotection using atorvastatin (sortis)

Conditions: Chronic Kidney Disease; Proteinuria

Summary: the main purpose of the study is find whether the addition of statin (atorvastatin) to dual renin-angiotensin-aldosterone system blockade involving angiotensin converting enzyme inhibitor and at-1 angiotensin ii receptor blocker leads to the reduction of proteinuria, main prognostic marker of chronic kidney disease progression.

the renin-angiotensin-aldosterone system (raas) plays an important role in the progression of chronic kidney diseases (ckd), and inhibition of the raas with angiotensin-converting enzyme inhibitors (acei) and angiotensin ii type 1 receptor blockers (arb) may retard ckd progression. dual pharmacological blockade of the raas with acei and arb is recommended as a standard renoprotective management at least in patients with nondiabetic proteinuric ckd. however, neither acei nor arb, even in high doses or in concomitant usage, abrogate the progression of ckd completely. innovative approaches are needed to keep patients with ckd off dialysis. additional statin (atorvastatin) pathway may prove to be such beneficial therapeutic concept.given these facts additional administration of statin to combination treatment with acei and arb, may provide additional renal protection. to shed more light on this issue, we performed a randomised open controlled study to evaluate the influence of triple therapy with acei and/orarb and statin on surrogate markers of kidney injury, i.e. proteinuria, markers of tubular involvement and kidney fibrosis.

Eligibility criteria:
inclusion criteria: * chronic kidney disease * stable proteinuria above 300 mg/24 hours (no variations above 25% in the last 6 months) * normal or slightly impaired stable renal function defined as serum creatinine level below 1.7 mg/dl (egfr \> 45 ml/min) exclusion criteria: * nephrotic syndrome * steroids or other immunosuppressive treatment minimum during six months before the study * diabetes mellitus * potassium serum level \> 5.1 meq/l * albumin serum level \< 2.0mg/dl * creatinine serum level \>2 mg/dl * current diagnosis of heart failure new york heart association (nyha) class ii-iv * clinically significant valvular heart disease or second or third degree heart block without a pacemaker * history of hypertensive encephalopathy, cerebrovascular accident or transient ischemic cerebral attack * history of myocardial infarction, unstable angina pectoris, coronary bypass surgery, or any percutaneous coronary intervention * history of malignancy including leukemia and lymphoma (but not basal cell skin carcinoma) within the past five years * pregnant or nursing women * any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of study drugs. * history of alcohol abuse * nsaid abuse (more than 2 doses per week) * known or suspected contraindications to the study medications, including history of allergy to ace inhibitors, at-1 receptor blockers and atorvastatin

Keywords: proteinuria, atorvastatin
relationship between ectopic pregnancy and thyroid disorders

Conditions: Ectopic Pregnancy; Thyroid Diseases; Pregnancy, Ectopic

Summary: fallopian tubes participate in the incorporation of gametes and embryos into the endometrial cavity. it also provides an optimal environment for flattening and early embryonic development. tubal pathologies can cause both primary and secondary infertility. this condition has been associated with overt and subclinical hypothyroidism. however, the effects of hypothyroidism on tubal activity are not fully known. although a few animal experiment studies on this subject have been published, there is no study on this subject in the literature. demonstrating that epithelial and smooth muscle cells of rat fallopian tubes express thyroid receptors in animal experiments showed that fallopian tubes are targets for thyroid hormones. again, in an animal experiment study, it was revealed that thyroid hormones have an important control on glycogen and lipid storage, lipid signaling and lymphocyte infiltration, which have an important role in maintaining the microenvironment in the rat fallopian tubes. this microenvironment is necessary for fertilization, sperm capacitation and gamete development. in another animal experimental study, it was thought that changes in the size of the epithelium of the fallopian tubes and cell metabolism in hypothyroid rabbits may affect oviductal activity and reproductive functions. an ectopic pregnancy is defined as a pregnancy implanted outside of the uterus. ectopic pregnancy \>98% implants in the fallopian tube. the etiology of ectopic pregnancy is unclear, but tubal implantation is probably due to impaired embryo-tubal transport. this is due to changes in the tubal environment. based on this information, we aim to determine the possible relationship between hypothyroidism and ectopic pregnancy in humans in our study.

our aim in this study is to determine the possible relationship between hypothyroidism and ectopic pregnancy in humans. for this purpose, 40 patients with a diagnosis of ectopic pregnancy and 40 patients with diagnosis of early pregnancy followed in siirt training and research hospital between 30 june 2022 and 30 october 2022 will be included in the study. the patient's age, pregnancy history, medical history and laboratory findings (tsh, st3, st4, tt3, tt4, thryoglobulin , anti-peroxidase antibody, anti-thryoglobulin antibody, tsh receptors antibody ) will be recorded. in the light of the information gathered, it will be tried to determine whether there is a relationship between thyroid dysfunctions and ectopic pregnancy.

Eligibility criteria:
inclusion criteria: * \>18 years of age * having an early pregnancy or ectopic pregnancy exclusion criteria: * using medications due to thyroid gland dysfunction * history of ectopic pregnancy * history of tubal surgery

Keywords: thyroid disorders pregnancy ectopic
impact of a multidisciplinary assessment in day hospitalization versus standard care on the deployment of supportive oncology care recommended by the personalized post-cancer plan in patients at the end of initial treatment for gynecological ovarian and endometrial cancer endometrial cancer

Conditions: Gynecologic Cancer; Remission

Summary: this project proposes a structuring of supportive oncology care for the recovery phase after gynecological cancer (ovarian/trope/peritoneum or endometrium). patients will be divided into three groups based on the identification of oncological support care needs. patients with supportive oncology care needs will be randomized into two groups: the experimental group, receiving a personalized post-cancer plan with a multidisciplinary assessment of supportive oncology care needs in a day hospital and coordinated follow-up by the referring study nurse, and the control group, receiving a personalized post-cancer plan without a day hospital. randomization will be stratified according to tumor location (ovary vs. endometrium), use of supportive oncology care during treatment, and treatment center. patients with no need for supportive oncology care will be followed in an observational cohort. the main objective is to identify and manage the supportive oncology care needs of patients in remission from endometrial or ovarian cancer to improve their quality of life and post-treatment follow-up. a medico-economic analysis will be performed.


Eligibility criteria:
inclusion criteria: * patient \> 18 years * patients in remission from first-line treatment of endometrial or ovarian/tumor/peritoneal cancer. * patient who has completed her initial treatment; patients on maintenance therapy are eligible. * fluency in french * patient with access to a telephone line * patient affiliated to a social security scheme * signature of informed consent prior to any specific study procedure exclusion criteria: * any associated medical or psychiatric condition that could compromise the patient's ability to participate in the study * patient with locoregional or metastatic recurrence * patient deprived of liberty, under guardianship or curatorship * simultaneous participation in a therapeutic clinical trial

Keywords: supportive oncology care personalized post-cancer plan
randomized study for minimally invasive splinted implants

Conditions: Jaw, Edentulous

Summary: the purpose of this study was to evaluate the effect of a integrated system for inserting two splinted minimally-invasive implants, to retain mandibular over dentures, on the quality of life of edentulous patients.


Eligibility criteria:
inclusion criteria: * edentulous * men and women * between 45 and 90 years of age * who had a persistent loss of stability and retention of their conventional mandibular dentures * without temporomandibular disorders exclusion criteria: * uncontrolled systemic disease (eg, hypertension, diabetes) * severe osteoporosis (bone mineral density \> 2.5 sd below the young adult reference mean, plus 1 or more fragility fractures) and/or taking bisphosphonates * mental disorders * who had received radiotherapy in the 18 months prior to the trial

Keywords: mini-dental implant implant-supported dental prosthesis minimally invasive surgical procedures overdentures aged
impact of environmental exposure at home address on one-year post-myocardial infarction survival

Conditions: Myocardial Infarction

Summary: numerous studies have explored the effects of environmental exposure to noise, air pollution and proximity to "natural" areas on various conditions. however, very few studies have focused on the "post-diagnosis" follow-up of patients after hospitalization for an ischemic cardiovascular episode and, to our knowledge, none have examined patient evolution at one year after myocardial infarction. thus, the real influence of factors and pollutants widely represented in the urban environment, in particular air pollution, noise pollution, and proximity and accessibility to natural areas ("green" or "blue" spaces), on the evolution of post-myocardial infarction at one year remains to be identified and quantified. the objective of the envi-mi project is to evaluate the impact of environmental exposure in the place of residence (noise, air pollution, proximity to "natural" spaces) on the evolution of post-myocardial infarction at one year within the dijon metropolitan area.


Eligibility criteria:
inclusion criteria: patient : * registered in the rico database * hospitalized for mi between january 1, 2002 and december 31, 2008, * whom residence is located in one of the 15 communes of the dijon urban unit (except for patients living in the area subject to the noise exposure plan of the military airport) exclusion criteria: na
study of the safety and effectiveness of esmirtazapine in participants with chronic primary insomnia (p05706)

Conditions: Insomnia

Summary: the purpose of this study is to determine if esmirtazapine (org 50081) is a safe and effective treatment for insomnia. it was anticipated that esmirtazapine would increase mean total sleep time (tst) as recorded in sleep diaries relative to placebo.


Eligibility criteria:
inclusion criteria: * has signed written informed consent after the scope and nature of the investigation was explained to them * has difficulty falling asleep, maintaining sleep or has early morning awakenings exclusion criteria: * significant medical or psychiatric illness causing sleep disturbances * has a history of bipolar disorder or family (immediate family) of suicide * has sleep disorder such as sleep related breathing disorder, restless leg syndrome, narcolepsy * has significant other medical illness such as acute or chronic pain, heart, kidney or liver disease within the last year * currently diagnosed or meets the criteria for major depressive disorder (mdd) or has been treated for mdd with the last 2 years * substance abuse, excessive use of alcohol (as determined by the physician) or drug addiction within the last year.